natgillin/translations-raw huggingface dataset:
means for moving the internal wall relative to the outer envelope, so as to make the respective volumes of each compartment to vary. 
sredstva za pomicanje unutarnjeg zida koje je razmjerno vanjskom omotaču, tako da tvori odgovarajuće volumene svakog od odjeljaka promjenjivim.
The closed loop system of claim 19, further comprising one or more of a glucose sensor, a delivery system to deliver the hyaluronan degrading enzyme and fast-acting insulin, and software programmed to integrate the pumping and monitoring functions, whereby the hyaluronan degrading enzyme and fast-acting insulin are delivered to achieve glycemic control that mimics the glycemic control in a non-diabetic subject. 
Sustav sa zatvorenim krugom prema zahtjevu 19, koji dalje sadrži jedan ili više senzora glukoze, sustav za izdavanje namijenjen za izdavanje enzima koji razgrađuje hijaluronan i brzo djelujućeg inzulina, i softver programiran za integriranje funkcija pumpanja i nadzora, pri čemu se enzim koji razgrađuje hijaluronan i brzo djelujući inzulin izdaju tako da se ostvari glikemijska kontrola koja podražava glikemijsku kontrolu kod nedijabetičkog subjekta.
The antibody or antigen binding portion thereof of claim 1 for use according to claim 1, wherein heavy chain variable regions CDR1, CDR2, and CDR3 of the antibody or antigen binding portion thereof comprise the amino acid sequences of SEQ ID NO: 9, 10, and 11, respectively, and wherein light chain variable regions CDR1, CDR2, and CDR3 of the antibody or antigen binding portion thereof comprise the amino acid sequences of SEQ ID NO: 12,13, and 14, respectively. 
Protutijelo ili njegov dio koji veže antigen prema zahtjevu 1 za uporabu prema zahtjevu 1, naznačeno time da varijabilni dijelovi teškog lanca CDR1, CDR2, i CDR3 protutijela ili njegovog dijela koji veže antigen sadrže odgovarajuće sekvence aminokiseline od SEQ ID NO: 9, 10, i 11, te pri čemu varijabilni dio lakog lanca CDR1, CDR2, te CDR3 protutijela ili njegovog dijela koji veže antigen sadrže odgovarajuće sekvence aminokiseline iz SEQ ID NO: 12,13, i 14.
A monoclonal anti-properdin antibody or antigen binding portion thereof that binds specifically to SEQ ID NO: 2 and blocks the alternative pathway activation without affecting the classical pathway activation in a mammal for use as a medicament. 
Monoklonsko anti-properdinsko protutijelo ili njegov dio koji veže antigen koje se veže specifično na SEQ ID NO: 2 i blokira alternativnu aktivaciju puta bez da utječe na klasičnu aktivaciju puta kod sisavca naznačeno time da se koristi kao lijek.
The welding head according to claim 2, characterized in that the insulated wire conduit (166) is a ceramics tube arranged in the contact device (160). 
Glava za zavarivanje prema zahtjevu 2, naznačena time što je izolirani žičani vod (166) keramička cijev smještena u kontaktnom uređaju (160).
The electric arc-welding contact device according to claim 19 or 20, characterized in that the electrically insulated portion (166) comprises an electrically insulating tube. 
Kontaktni uređaj za elektrolučno zavarivanje prema zahtjevu 19 ili 20, naznačen time što električki izolirani dio (166) ima električku izolacijsku cijev.
A method or use according to claim 1 or claim 2 wherein the composition comprises a rotavirus having a VP4 gene comprising, in the nucleotide sequence, at least one of the following: an adenine base (A) at position 788, an adenine base (A) at position 802 and a thymine base (T) at position 501 from the start codon. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što pripravak sadrži rotavirus čiji gen VP4 ima, u nukleotidnom slijedu, najmanje jedno od sljedećeg: adeninsku bazi (A) na položaju 788, adeninsku bazu (A) na položaju 802 i timinsku bazu (T) na položaju 501 iza početnog kodona.
A method or use according to any of claims 1- 4 in which the composition comprises a rotavirus having a VP7 gene comprising, in the nucleotide sequence, at least one of the following: a thymine (T) at position 605, an adenine (A) at position 897 and a guanine (G) at position 897 from the start codon. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačena time što pripravak sadrži rotavirus čiji gen VP7 ima, u nukleotidnom slijedu, najmanje jedno od sljedećeg: timin (T) na položaju 605, adenin (A) na položaju 897 i gvanin (G) na položaju 897 iza početnog kodona.
A method or use according to any preceding claim wherein the composition comprising an attenuated rotavirus strain of a G1P[8] type provides protection against severe rotavirus-induced gastroenteritis caused by infection of a rotavirus strain of a G2P[4] type. 
Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što pripravak sadrži oslabljeni soj rotavirusa tipa G1P[8] pruža zaštitu protiv teškog rotavirusnog gastroenteritisa s rezultatom jednakim ili većim od 11 na Vesikarijevoj skali, uzrokovanog infekcijomom soja rotavirusa tipa G2P[4].
A method or use according to any of claims 1 to 11 wherein the composition comprising an attenuated rotavirus strain of a G1 P[8] type is at least 40% protective, in a population of vaccinated individuals, against diarrhoea caused by a rotavirus strain which is of a G2P[4] type. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što pripravak sadrži oslabljeni soj rotavirusa tipa G1P[8] štiti najmanje 40%, u populaciji cijepljenih osoba, protiv proljeva uzrokovanog sojem rotavirusa koji je tipa G2P[4].
A method or use according to any of claims 1 to 16 wherein the composition comprises a G1P[8] rotavirus strain which is between 40% and 75% protective in a population of vaccinated individuals against severe gastro-enteritis caused by infection of rotaviruses with a G2P4 serotype. 
Upotreba u skladu s patentnim zahtjevom 8, naznačena time što pripravak štiti između 40% i 75% u populaciji osoba cijepljenih protiv teškog gastroenteritisa koje imaju rezultat jednak ili veći od 11 na Vesikarijevoj skali uzrokovan infekcijom serotipom G2P[4] rotavirusa.
The peptide as claimed in any one of claims 1 to 2 for use according to claim 8, wherein the pathology associated with impaired pancreatic function is selected from type 1 diabetes, new onset type 1 diabetes, type 2 diabetes, latent autoimmune diabetes of adulthood, pre-diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistant syndrome, metabolic syndrome/dysmetabolic syndrome, overweightness, obesity, hyperlipidemia, hypertriglyceridemia, eating disorders, anovulatory cycles and polycystic ovarian syndrome. 
Peptid prema bilo kojem od zahtjeva 1 do 2 za uporabu prema zahtjevu 8, gdje se patologija povezana s poremećajem funkcije gušterače izabire između dijabetesa tipa 1, novog dijabetesa tipa 1, dijabetesa tipa 2, latentnog autoimunog dijabetesa u odraslih, pre-dijabetesa, poremećaja glukoze natašte, poremećaja tolerancije na glukozu, sindroma otpornosti na inzulin, metaboličkog sindroma/dismetaboličkog sindroma, prekomjerne težine, pretilosti, hiperlipidemije, hipertrigliceridemije, poremećaja hranjenja, anovulatornih ciklusa i sindroma policističnih jajnika.
The compound according to claim 4 wherein: z is zero or 1. 
Spoj prema Zahtjevu 4, naznačen time, što je z jednako 0 ili 1.
The compound according to claim 10 wherein said compound is in crystalline FormN-1, which is characterized by one of the following: 
Spoj prema Zahtjevu 10, naznačen time, što je spomenuti spoj u kristalnom Obliku N-1, kojeg karakterizira jedno od slijedećih obilježja:
unit cell parameters substantially equal to the following: 
parametri jedinične stanice, koji su u biti jednaki sa ovima koji slijede:
a developer accommodating chamber (2k) for accommodating a developer; and a feeding portion (2c) for feeding the developer in said developer accommodating chamber (2k) with rotation of the feeding portion (2c); 
komore za prilagodbu razvijača (2k) za prilagođavanje razvijača; i opskrbnog dijela (2c) za opskrbu razvijača u navedenoj komori za prilagodbu razvijača(2k) s rotacijom opskrbnog dijela (2c);
a developer discharging chamber (3k) provided with a discharge opening (3e) for permitting discharging of the developer fed by said feeding portion (2c); 
komore za pražnjenje razvijača (3k) opremljene otvorom za pražnjenje (3e) za omogućavanje pražnjenja razvijača nakon što je opskrbljen navedenim opskrbnim dijelom (2c);
A developer supply container (1) according to Claim 1 or 2, wherein said drive converting portion (2d, 3b) converts the rotational force so that an internal pressure of at least said developer discharging chamber (3h) changes between a pressure lower than an ambient pressure and a pressure higher than the ambient pressure with the reciprocation of said pump portion (2b). 
Spremnik za nadopunu razvijača (1) sukladno Zahtjevima 1 ili 2, gdje navedeni dio za pretvaranje pogona (2d, 3b) pretvara rotacijsku silu tako da se unutarnji pritisak barem navedene komore za pražnjenje razvijača (3h) mijenja između pritiska nižeg od pritiska okoline i pritiska višeg od pritiska okoline s resiprocitetom navedenog dijela za ubrizgavanje (2b).
A developer supply container (1) according to any one of Claims 1 - 4, furthermore comprising a developer, wherein the developer in said developer supply container (1) has a fluidity energy of not less than 4.3x 10-4 kg.cm2/s2 and not more than 4.14x 10-3 kg.cm2/s2, and wherein said discharge opening (3a) has an area not more than 12.6 mm2. 
Spremnik za nadopunu razvijača (1) sukladno bilo kojem od Zahtjeva 1 - 4, nadalje sadrži razvijač, pri čemu razvijač u navedenom spremniku za nadopunjavanje (1) ima energiju fluidnosti ne manju od 4.3x 10-4 kg.cm2/s2 i ne veću od 4.14x 10-3 kg.cm2/s2, i pri čemu navedeni otvor za pražnjenje (3a) ima površinu ne veću od 12.6 mm2.
A developer supply container (1) according to any one of Claims 1 - 5, wherein said drive converting portion (2d, 3b) converts the rotational force such that suction and delivery actions are alternately carried out through said discharge opening (3a) with the reciprocation of said pump portion (2b). 
Spremnik za nadopunu razvijača (1) sukladno bilo kojem od Zahtjeva 1 - 5, pri čemu navedeni dio za pretvaranje pogona (2d, 3b) pretvara rotacijsku silu tako da su postupci uvlačenja i ispuštanja izmjenično provedeni kroz navedeni otvor za pražnjenje (3a) s reciprocitetom s navedenim dijelom za ubrizgavanje (2b).
A developer supply container according to any one of Claims 1 - 9, further comprising a holding portion which is to be held by said developer replenishing apparatus (201) so that said developer discharging chamber (3h) is substantially non-rotatable, and said discharge opening (3a) is provided in a bottom portion of said developer discharging chamber (3h). 
Spremnik za nadopunu razvijača sukladno bilo kojem od Zahtjeva 1 – 9, nadalje sadrži držač koji drži navedeni uređaj za nadopunu razvijača (201) tako da navedena komora za pražnjenje (3h) supstancijalno ne može rotirati, a navedeni otvor za pražnjenje (3a) nalazi se na donjem dijelu navedene komore za pražnjenje (3h).
A developer supply container according to any one of Claims 14 or 15, wherein said partition (17) is rotatable integrally with said feeding portion (2c), or wherein said partition (17) is reciprocated by a force provided by conversion of said drive converting portion (2d, 3b). 
Spremnik za nadopunu razvijača sukladno bilo kojem od Zahtjeva 14 ili 15, pri čemu navedena podjela (17) može rotirati integralno s navedenim opskrbnim dijelom (2c) ili pri čemu je navedena podjela (17) recipročna sa silom konverzije navedenog dijela za pretvaranje pogona (2d, 3b).
A developer supply container according to Claim 17, wherein said nozzle portion (47) is provided with a plurality of such openings (51) around a free end side thereof. 
Spremnik za nadopunu razvijača sukladno Zahtjevu 17, pri čemu navedeni dio s mlaznicom (47) sadrži više otvora (51) oko slobodne strane iste.
A developer supply container according to any one of Claims 1 - 19, wherein said pump portion (2b) is capable of accommodating the developer therein and is rotatable integrally with said feeding portion (2c). 
Spremnik za nadopunu razvijača sukladno bilo kojem od Zahtjeva 1 – 19, pri čemu navedeni dio za ubrizgavanje (2b) ima sposobnost prilagodbe razvijača i rotira integralno s navedenim opskrbnim dijelom (2c).
A developer supplying system comprising a developer replenishing apparatus (201), the developer supply container (1) according to any of claims 1 to 21 being detachably mountable to said developer replenishing apparatus (201), said developer supplying system comprising: 
Sustav za nadopunu razvijača koji sadrži uređaj za nadopunu razvijača (201), spremnik za nadopunu razvijača (1) sukladno bilo kojem od Zahtjeva 1 do 21 odvojivo pričvršćen na navedeni uređaj za nadopunu razvijača (201), navedeni sustav nadopune sadrži:
A developer supply container according to claim 3, wherein with increase of a volume of a chamber of the pump portion, the pressure at least in the developer discharging chamber becomes negative. 
Spremnik za nadopunu razvijača (1) sukladno Zahtjevu 1, pri čemu s povećanjem volumena komore navedenog dijela za ubrizgavanje (2b), pritisak barem u navedenoj komori za pražnjenje razvijača (3h) postaje negativan.
A composition for sustained release of a biologically active polypeptide, comprising a biocompatible polymer having the biologically active polypeptide dispersed therein so as to be present at about 5% (w/w) of the weight of the composition, and a sugar dispersed therein so as to be present at about 2% (w/w) of the weight of the composition, wherein the biologically active polypeptide is a glucoregulatory peptide, wherein a total pore volume of the composition is about 0.1 mL/g or less as determined using mercury intrusion porosimetry and wherein the composition is free from buffer and salting out salts. 
Oblik s produljenim oslobađanjem biološki aktivnog polipeptida, sadrži biokompatibilni polimer s biološki aktivnim polipeptidom dispergiranim u njemu tako da je prisutan u količini od 3% (w/w) do 10% (w/w) težine oblika, i sa saharozom dispergiranom u njemu tako da je ima u količini od 2% (w/w) težine oblika, gdje je biološki aktivni polipeptid eksendin-4, gdje je ukupni volumen pora u obliku 0,1 ml/g ili manji, kako je izmjereno živinom intruzijskom porozimetrijom, i gdje u obliku nema pufera i soli za isoljavanje.
The method according to Claim 1, characterized in that a PTT version number corresponding to the function of the mobile station is stored in the mobile station. 
Postupak prema zahtjevu 1, naznačen time da je broj PTT verzije koji odgovara funkciji mobilne stanice pohranjen u mobilnoj stanici.
The method according to Claim 2, characterized in that if the PTT version number of the mobile station is 1, it corresponds to PTT enhanced group call; if the PTT version number of the mobile station is 2, it corresponds to supporting a quick call access of the mobile station; if the PTT version number of the mobile station is 3, it corresponds to supporting a big group paging of the mobile station; if the PTT version number of the mobile station is 5, it corresponds to supporting a minus slot paging and the first stage of a PPT traditional group call of the mobile station; if the PTT version number of the mobile station is 6, it corresponds to the mobile station supporting a supplementary channel transmitting signaling and the second stage of the PPT traditional group call. 
Postupak prema zahtjevu 2, naznačen time da kada je broj PTT verzije mobilne stanice 1, to odgovara PTT poboljšanom skupnom pozivu; kada je broj PTT verzije mobilne stanice 2, to odgovara podršci za brzi pristup pozivu mobilne stanice; kada je broj PTT verzije mobilne stanice 3, to odgovara podršci za jednosmjernom pozivanju velike skupine mobilne stanice; kada je broj PTT verzije mobilne stanice 5, to odgovara podršci za minus slot jednosmjerno pozivanje i prvoj fazi PTT uobičajenog skupnog poziva mobilne stanice; kada je broj PTT verzije mobilne stanice 6, to odgovara da mobilna stanica podržava signalizaciju prijenosa na dopunskom kanalu i drugoj fazi PTT uobičajenog skupnog poziva.
The method according to Claim 5, characterized in that the PTT version number corresponding to the function of the mobile station is stored in the mobile station, and the mobile station not supporting the minus slot function means the PTT version number is less than 4. 
Postupak prema zahtjevu 5, naznačen time da broj PTT verzije pohranjen u mobilnoj stanici odgovara funkciji mobilne stanice, te kada mobilna stanica ne podržava funkciju minus slot znači da je broj PTT verzije manji od 4.
is chosen from hydrogen, hydroxyl, an optionally substituted alkyl group having 1 to 4 carbons, phosphate, sulfate, -OR7, a protecting group, and a saccharide; 
je odabran od vodika, hidroksila, po izboru supstituirana alkilna skupina koja ima 1 do 4 atoma ugljika, fosfat, sulfat, -OR7, zaštitna skupina, te saharid;
treating a compound having the Formula VIIIA: wherein: 
obradu spoja koji ima Formulu VIIIA:
The method of claim 10, wherein the tetraalkylammonium halide is tetrabutylammonium iodide. 
Postupak prema zahtjevu 10, naznačen time da tetraalkilamonijev halid je tetrabutilamonijev jodid.
The method of claim 1, further comprising the step of varying the positions and identities of the protecting groups in said compound, including adding additional protecting groups to said compound. 
Postupak prema zahtjevu 1, naznačen time da dodatno sadrži korak mijenjanja položaja i identiteta zaštitnih skupina u navedenom spoju, uključujući dodavanje dodatnih zaštitnih skupina navedenom spoju.
The method of claim 20, wherein the product of said method is a compound of Formula 
Postupak prema zahtjevu 20, naznačen time da proizvod navedenog postupka je spoj s Formulom [image] .
A compound having the structure: 
obradu spoja koji ima Formulu VIIIA:
A composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of the compound or therapeutically acceptable salt of any one of claims 1-8. 
Pripravak za liječenje raka mokraćnog mjehura, raka mozga, raka dojke, raka koštane srži, raka grlića maternice, kronične limfocitne leukemije, raka debelog crijeva, raka jednjaka, raka jetre, limfoblastične leukemije, folikularnih limfoma, limfoidne malignosti T-stanica ili B-stanica, melanoma, mijeloične leukemije, mijeloma, raka usne šupljine, raka jajnika, raka ne-malih plućnih stanica, raka prostate, raka pluća malih stanica ili raka slezene, naznačen time, da navedeni pripravak sadrži pomoćno sredstvo i terapijski učinkovitu količinu spoja ili terapijski prihvatljivu sol prema patentnom zahtjevu 1 ili 2.
The compound of any one of claims 1-8 or a therapeutically acceptable salt thereof for use in treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, by administering to said patient a therapeutically effective amount of said compound or therapeutically acceptable salt thereof. 
Spoj ili terapijski prihvatljiva sol u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da se koristi u liječenju raka mokraćnog mjehura, raka mozga, raka dojke, raka koštane srži, raka vrata maternice, kronične limfocitne leukemija, karcinoma debelog crijeva, raka jednjaka, raka jetre, limfoblastične leukemije, folikularnih limfoma, limfoidne malignosti T-stanica ili B-stanica, melanoma, mijelogene leukemije, mijeloma, raka usne šupljine, raka jajnika, raka ne-malih plućnih stanica, raka prostate, raka malih plućnih stanica ili raka slezene kod pacijenta.
a light chain variable region having at least about 90% sequence identity to SEQ ID NO:13 or SEQ ID NO:19. 
varijabilno područje slabog lanca, koje ima najmanje oko 90% identiteta sekvence od SEQ ID NO:13 ili SEQ ID NO:19.
A compound, or a therapeutically acceptable salt thereof, wherein the compound is selected from the group consisting of: 
Spoj ili njegova terapijski prihvatljiva sol, naznačen time, da je spoj odabran iz skupine koja se sastoji od:
A composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of the compound or therapeutically acceptable salt of claim 1 or 2. 
Pripravak za liječenje raka mokraćnog mjehura, raka mozga, raka dojke, raka koštane srži, raka grlića maternice, kronične limfocitne leukemije, raka debelog crijeva, raka jednjaka, raka jetre, limfoblastične leukemije, folikularnih limfoma, limfoidne malignosti T-stanica ili B-stanica, melanoma, mijeloične leukemije, mijeloma, raka usne šupljine, raka jajnika, raka ne-malih plućnih stanica, raka prostate, raka pluća malih stanica ili raka slezene, naznačen time, da navedeni pripravak sadrži pomoćno sredstvo i terapijski učinkovitu količinu spoja ili terapijski prihvatljivu sol prema patentnom zahtjevu 1 ili 2.
The compound or therapeutically acceptable salt of claim 1 or 2 for use in treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient. 
Spoj ili terapijski prihvatljiva sol u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da se koristi u liječenju raka mokraćnog mjehura, raka mozga, raka dojke, raka koštane srži, raka vrata maternice, kronične limfocitne leukemija, karcinoma debelog crijeva, raka jednjaka, raka jetre, limfoblastične leukemije, folikularnih limfoma, limfoidne malignosti T-stanica ili B-stanica, melanoma, mijelogene leukemije, mijeloma, raka usne šupljine, raka jajnika, raka ne-malih plućnih stanica, raka prostate, raka malih plućnih stanica ili raka slezene kod pacijenta.
POLY1 is a first poly(ethylene glycol) having a weight average molecular weight in the range of greater than 5,000 Daltons to 100,000 Daltons; 
POLY1 je prvi poli(etilen glikol) koji ima molekularnu težinu u rasponu od više od 5,000 Daltona do 100,000 Daltona;
is a second spacer moiety; 
H je ionizirajući atom vodika;
The polymeric reagent of claim 1, wherein the functional group capable of reacting with an amino group of an active agent is selected from the group consisting of carbonates of N-succinimidyl, 1-benzotriazolyl, imidazole, imidazole, halides and phenolates. 
Polimerni reagens prema zahtjevu 1, naznačen time da je funkcionalna skupina koja može reagirati s amino skupinom aktivnog sredstva odabrana iz skupine koja se sastoji od karbonata N-sukcinimidila, 1-benzotriazolila, imidazola, imidazola, halida i fenolata.
The polymeric reagent of claim 1, wherein the functional group capable of reacting with an amino group is a carbonate of N-succinimidyl. 
Polimerni reagens prema zahtjevu 1, naznačen time da funkcionalna skupina koja može reagirati s amino skupinom je karbonat N-sukcinimidila.